Short amyloid-β (Aβ) immunogens reduce cerebral Aβ load and learning deficits in an Alzheimer's disease mouse model in the absence of an Aβ-specific cellular immune response

Journal of Neuroscience

Volumn 26, Issue 18, 2006, Pages 4717-4728

  Maier, Marcel ^a   Seabrook, Timothy J ^a   Lazo, Noel D ^b   Jiang, Liying ^a   Das, Pritam ^c   Janus, Christopher ^c   Lemere, Cynthia A ^a,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MAYO CLINIC   (United States)

^d Center for Neurologic Diseases   (United States)

Author keywords

A peptide; Alzheimer's disease; Amyloid beta; Behavior; Immunotherapy; Intranasal; T cell

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-15]; AMYLOID PRECURSOR PROTEIN; ESCHERICHIA COLI ENTEROTOXIN; UNCLASSIFIED DRUG; ANTIBODY; BACTERIAL TOXIN; CYTOKINE; ENTEROTOXIN; ENTEROTOXIN LT; ESCHERICHIA COLI PROTEIN; PEPTIDE FRAGMENT; VACCINE;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; BEHAVIORAL SCIENCE; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; HELPER CELL; IMMUNE RESPONSE; IMMUNIZATION; LEARNING DISORDER; MALE; MEMORY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN MOTIF; TANDEM REPEAT; ANALYSIS OF VARIANCE; ANIMAL; ANIMAL BEHAVIOR; ANTIBODY SPECIFICITY; BIOPHYSICS; BLOOD; BRAIN LEVEL; C57BL MOUSE; COMPARATIVE STUDY; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; GENETICS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; MAZE TEST; METABOLISM; METHODOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; T LYMPHOCYTE; TIME; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANALYSIS OF VARIANCE; ANIMALS; ANTIBODIES; ANTIBODY SPECIFICITY; BACTERIAL TOXINS; BEHAVIOR, ANIMAL; BIOPHYSICS; BRAIN CHEMISTRY; CELL PROLIFERATION; CYTOKINES; DISEASE MODELS, ANIMAL; ENTEROTOXINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; ESCHERICHIA COLI PROTEINS; IMMUNIZATION, SECONDARY; IMMUNOHISTOCHEMISTRY; LEARNING DISORDERS; MALE; MAZE LEARNING; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; T-LYMPHOCYTES; TIME FACTORS; VACCINES;

EID: 33646938005     PISSN: 02706474     EISSN: 02706474     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.0381-06.2006     Document Type: Article

References (64)

1. Agadjanyan MG, Ghochikyan A, Petrushina I, Vasilevko V, Movsesyan N, Mkrtichyan M, Saing T, Cribbs DH (2005) Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from α-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol 174:1580-1586.
2. Ahlers JD, Takeshita T, Pendleton CD, Berzofsky JA (1997) Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence. Proc Natl Acad Sci USA 94:10856-10861.
3. Banks WA, Terrell B, Farr SA, Robinson SM, Nonaka N, Morley JE (2002) Passage of amyloid beta protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease. Peptides 23:2223-2226.
4. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, et al. (2000) Peripherally administered antibodies against amyloid betapeptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6:916-919.
5. Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, Guido T, Hoenow K, Hu K, Johnson-Wood K, Khan K, Kholodenko D, Lee C, Lee M, Motter R, Nguyen M, Reed A, Schenk D, Tang P, Vasquez N, et al. (2003) Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci USA 100:2023-2028.
6. Cain D, Beiko J, Boon F (1997) Navigation in the water maze: the role of proximal and distal visual cues, path integration, and magnetic field information. Psychobiology 25:286-293.
7. Cease KB, Margalit H, Cornette JL, Putney SD, Robey WG, Ouyang C, Streicher HZ, Fischinger PJ, Gallo RC, DeLisi C, Berzofsky JA (1987) Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide. Proc Natl Acad Sci USA 84:4249-4253.
8. Citron M (2004) Strategies for disease modification in Alzheimer's disease. Nat Rev Neurosci 5:677-685.
9. Cribbs D, Ghochikyan A, Vasilevko V, Tran M, Petrushina I, Sadzikava N, Babikyan D, Kesslak P, Kieber-Emmons T, Cotman C, Agadjanyan M (2003) Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol 15:505-514.
10. Deane R, Sagare A, Hamm K, Parisi M, LaRue B, Guo H, Wu Z, Holtzman DM, Zlokovic BV (2005) IgG-assisted age-dependent clearance of Alzheimer's amyloid β peptide by the blood-brain barrier neonatal Fc receptor. J Neurosci 25:11495-11503.
11. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM (2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 98:8850-8855.
12. Dickinson BL, Clements JD (1995) Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect Immun 63:1617-1623.
13. Dodart J-C, Bales K, Gannon K, Greene S, DeMattos R, Mathis C, DeLong C, Wu S, Wu X, Holtzman D, Paul S (2002) Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model. Nat Neurosci 5:452-457.
14. Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, Costa-Jussa F (2004) Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 14:11-20.
15. Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M (2005) Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64:1563-1572.
16. Frautschy SA, Yang F, Irrizarry M, Hyman B, Saido TC, Hsiao K, Cole GM (1998) Microglial response to amyloid plaques in APPsw transgenic mice. Am J Pathol 152:307-317.
17. Frenkel D, Katz O, Solomon B (2000) Immunization against Alzheimer's beta-amyloid plaques via EFRH phage administration. Proc Natl Acad Sci USA 97:11455-11459.
18. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Boada Rovira M, Forette F, Orgogozo JM (2005) Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64:1553-1562.
19. Gordon MN, Holcomb LA, Jantzen PT, DiCarlo G, Wilcock D, Boyett KW, Connor K, Melachrino J, O'Callaghan JP, Morgan D (2002) Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. Exp Neurol 173:183-195.
20. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353-356.
21. Hart MK, Palker TJ, Matthews TJ, Langlois AJ, Lerche NW, Martin ME, Scearce RM, McDanal C, Bolognesi DP, Haynes BF (1990) Synthetic peptides containing T and B cell epitopes from human immunodeficiency virus envelope gp120 induce anti-HIV proliferative responses and high titers of neutralizing antibodies in rhesus monkeys. J Immunol 145:2677-2685.
22. Hartman RE, Izumi Y, Bales KR, Paul SM, Wozniak DF, Holtzman DM (2005) Treatment with an amyloid-β antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer's disease. J Neurosci 25:6213-6220.
23. Haynes BF, Arthur LO, Frost P, Matthews TJ, Langlois AJ, Palker TJ, Hart MK, Scearce RM, Jones DM, McDanal C (1993) Conversion of an immunogenic human immunodeficiency virus (HIV) envelope synthetic peptide to a tolerogen in chimpanzees by the fusogenic domain of HIV gp41 envelope protein. J Exp Med 177:717-727.
24. Janus C (2004) Search strategies used by APP transgenic mice during navigation in the Morris water maze. Learn Mem 11:337-346.
25. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, St George-Hyslop P, Westaway D (2000) A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408:979-982.
26. Jensen MT, Mottin MD, Cracchiolo JR, Leighty RE, Arendash GW (2005) Lifelong immunization with human beta-amyloid (1-42) protects Alzheimer's transgenic mice against cognitive impairment throughout aging. Neuroscience 130:667-684.
27. Johnson Jr WC (1990) Protein secondary structure and circular dichroism: a practical guide. Proteins 7:205-214.
28. Kitazawa M, Oddo S, Yamasaki TR, Green KN, LaFerla FM (2005) Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J Neurosci 25:8843-8853.
29. Lee M, Bard F, Johnson-Wood K, Lee C, Hu K, Griffith SG, Black RS, Schenk D, Seubert P (2005) Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies. Ann Neurol 58:430-435.
30. Lemere C, Spooner E, LaFrancois J, Malester B, Mori C, Leverone J, Matsuoka Y, DeMattos R, Holtzman D, Clements J, Selkoe D, Duff K (2003) Evidence for peripheral clearance of Aβ following chronic, active Aβ immunization in PSAPP mice. Neurobiol Dis 14:10-18.
31. Lemere CA, Maron R, Spooner ET, Grenfell TJ, Mori C, Desai R, Hancock WW, Weiner HL, Selkoe DJ (2000) Nasal A beta treatment induces anti-A beta antibody production and decreases cerebral amyloid burden in PD-APP mice. Ann NY Acad Sci 920:328-331.
32. Lemere CA, Spooner ET, Leverone JF, Mori C, Clements JD (2002) Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants. Neurobiol Aging 23:991-1000.
33. Lemere CA, Beierschmitt A, Iglesias M, Spooner ET, Bloom JK, Leverone JF, Zheng JB, Seabrook TJ, Louard D, Li D, Selkoe DJ, Palmour RM, Ervin FR (2004) Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am J Pathol 165:283-297.
34. Leverone JF, Spooner ET, Lehman HK, Clements JD, Lemere CA (2003) Abeta1-15 is less immunogenic than Abeta1-40/42 for intranasal immunization of wild-type mice but may be effective for "boosting." Vaccine 21:2197-2206.
35. Levites Y, Das P, Price RW, Rochette MJ, Kostura LA, McGowan EM, Murphy MP, Golde TE (2006) Anti-Abeta(42)- and anti-Abeta(40)-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J Clin Invest 116:193-201.
36. Maier M, Seabrook TJ, Lemere CA (2005a) Developing novel immunogens for an effective, safe Alzheimer's disease vaccine. Neurodegenerative Dis 2:267-272.
37. Maier M, Seabrook TJ, Lemere CA (2005b) Modulation of the humoral and cellular immune response in Abeta immunotherapy by the adjuvants monophosphoryl lipid A (MPL), cholera toxin B subunit (CTB) and E. coli enterotoxin LT(R192G). Vaccine 23:5149-5159.
38. Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, Seubert P, Games D, Kirby L, Schenk D (2005) Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64:129-131.
39. McLaurin J, Cecal R, Kierstead M, Tian X, Phinney A, Manea M, French J, Lambermon M, Darabie A, Brown M, Janus C, Chishti M, Horne P, Westaway D, Fraser P, Mount H, Przybylski M, St George-Hyslop P (2002) Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 8:1263-1269.
40. Mecham RP (1991) Laminin receptors. Annu Rev Cell Biol 7:71-91.
41. Monsonego A, Maron R, Zota V, Selkoe DJ, Weiner HL (2001) Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease. Proc Natl Acad Sci USA 98:10273-10278.
42. Monsonego A, Zota V, Karni A, Krieger JI, Bar-Or A, Bitan G, Budson AE, Sperling R, Selkoe DJ, Weiner HL (2003) Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest 112:415-422.
43. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW (2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408:982-985.
44. Morris RG, Garrud P, Rawlins JN, O'Keefe J (1982) Place navigation impaired in rats with hippocampal lesions. Nature 297:681-683.
45. Mucke L, Masliah E, Yu G-Q, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L (2000) High-level neuronal expression of Aβ1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 20:4050-4058.
46. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9:448-452.
47. Oishi Y, Onozuka A, Kato H, Shimura N, Imai S, Nisizawa T (2001) The effect of amino acid spacers on the antigenicity of dimeric peptide-inducing cross-reacting antibodies to a cell surface protein antigen of Streptococcus mutans. Oral Microbiol Immunol 16:40-44.
48. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C (2003) Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61:46-54.
49. O'Toole M, Janszen DB, Slonim DK, Reddy PS, Ellis DK, Legault HM, Hill AA, Whitley MZ, Mounts WM, Zuberek K, Immermann FW, Black RS, Dorner AJ (2005) Risk factors associated with beta-amyloid(1-42) immunotherapy in preimmunization gene expression patterns of blood cells. Arch Neurol 62:1531-1536.
50. Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, Mathews PM, Jucker M (2002) Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 298:1379.
51. Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, Piroozi KS, Jordan WH, Brown DD, Hoffman WP, Holtzman DM, Bales KR, Gitter BD, May PC, Paul SM, DeMattos RB (2005) Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid β. J Neurosci 25:629-636.
52. Rogers J, Strohmeyer R, Kovelowski C, Li R (2002) Microglia and inflammatory mechanisms in the clearance of amyloid beta peptide. Glia 40:260-269.
53. Ruoslahti E (1988) Fibronectin and its receptors. Annu Rev Biochem 57:375-413.
54. Ruoslahti E (1996) RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 12:697-715.
55. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vendevert C, et al. (1999) Immunization with amyloid-beta attenuates Alzheimer-diseaselike pathology in the PDAPP mouse. Nature 400:173-177.
56. Seabrook TJ, Bloom JK, Iglesias M, Spooner ET, Walsh DM, Lemere CA (2004) Species-specific immune response to immunization with human versus rodent A beta peptide. Neurobiol Aging 25:1141-1151.
57. Sigurdsson EM, Knudsen E, Asuni A, Fitzer-Attas C, Sage D, Quartermain D, Goni F, Frangione B, Wisniewski T (2004) An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-β derivatives. J Neurosci 24:6277-6282.
58. Town T, Tan J, Sansone N, Obregon D, Klein T, Mullan M (2001) Characterization of murine immunoglobulin G antibodies against human amyloid-β1-42. Neurosci Lett 307:101-104.
59. Townsend KP, Obregon D, Quadros A, Patel N, Volmar C, Paris D, Mullan M (2002) Proinflammatory and vasoactive effects of Abeta in the cerebrovasculature. Ann NY Acad Sci 977:65-76.
60. Walsh DM, Selkoe DJ (2004) Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44:181-193.
61. Weiner HL, Lemere CA, Maron R, Spooner ET, Grenfell TJ, Mori C, Issazadeh S, Hancock WW, Selkoe DJ (2000) Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann Neurol 48:567-579.
62. Wilcock DM, Rojiani A, Rosenthal A, Levkowitz G, Subbarao S, Alamed J, Wilson D, Wilson N, Freeman MJ, Gordon MN, Morgan D (2004a) Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci 24:6144-6151.
63. Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, Morgan D (2004b) Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 1:24.
64. Yano A, Onozuka A, Matin K, Imai S, Hanada N, Nisizawa T (2003) RGD motif enhances immunogenicity and adjuvanticity of peptide antigens following intranasal immunization. Vaccine 22:237-243.